#United States #San Diego #AI Drug Discovery #BioDuro #Atombeat Inc.

Atombeat and BioDuro Unveil Groundbreaking AI Platform

On July 30, 2025, Atombeat Inc., a significant player in AI-driven drug discovery, announced a strategic partnership with BioDuro, a well-respected organization in the field of Contract Research, Development, and Manufacturing (CRDMO). Together, they are set to launch an AI-powered platform that aims to accelerate peptide drug discovery, marking a pivotal advancement in pharmaceutical research and development.

The Collaboration

This partnership merges the cutting-edge AI capabilities of Atombeat with BioDuro's extensive expertise in discovery chemistry and biology. By integrating Atombeat’s in silico modeling approach and AI-accelerated data-driven design, both companies work toward streamlining the entire peptide development process. The goal is not only to create high-quality cyclic peptides but to do so in a significantly reduced timeframe and at a cost-effective scale.

The Technology Behind the Innovation

Atombeat harnesses its proprietary Hermite® software and RiDYMO® platform, bolstered by advanced technologies like Reinforced Dynamics and Uni-Dock. This unique combination allows for the exploration of an unparalleled range of potential peptide compounds—over one trillion—sourced from more than 1000 natural and synthetic amino acids, all in silico before any laboratory testing takes place.

The platform focuses on exploring key developability traits, such as membrane permeability, rapidly filtering and prioritizing compounds that show the most promise. This process is crucial for expediting the early stages of drug discovery, allowing researchers to concentrate only on the most viable candidates while conserving time, resources, and funding.

From Design to Synthesis

Once the design phase is finalized, BioDuro employs its high-throughput synthesis capability to manufacture hundreds of peptide compounds simultaneously. Within just a week, BioDuro can deliver high-purity peptides ready for biological testing, eliminating the need for lengthy purification processes. This efficient combination of in silico design with wet-lab validation significantly shortens research and development timelines and minimizes both costs and risks associated with drug development.

Dr. Armin Spura, CEO of BioDuro, expressed his enthusiasm: "We are excited to advance peptide innovation through our strategic partnership with Atombeat. Their extensive experience in AI-assisted drug design and optimization complements our own expertise in peptide synthesis exceptionally well. Together, we aim to provide the industry with leading services in peptide drug development."

A Shared Vision for Innovation

Dr. Dongdong Wang, co-founder of Atombeat, echoed these sentiments, stating, "Our commitment lies in integrating AI with experimental processes to create an intelligent, comprehensive platform for peptide drug evaluation and discovery. Our collaboration is dedicated to fostering innovation in pharmaceutical development, ultimately addressing unmet clinical needs around the globe."

About the Companies

BioDuro

Founded nearly three decades ago, BioDuro operates globally with a presence across seven locations in the United States and China, employing over 2,000 professionals. They specialize in both small and large molecule discovery and are recognized for their comprehensive services, spanning early drug discovery to commercial manufacturing in chemistry and biology, including drug metabolism and pharmacokinetics (DMPK).

Atombeat

Atombeat Inc., headquartered in New Jersey, champions the integration of advanced computational techniques into drug discovery. Founded by elite medicinal and computational chemists, Atombeat strives to make sophisticated computational tools accessible. They provide a suite of potent drug design software and early development services aimed at tackling complex pharmaceutical targets and exploring new therapeutic modalities.

Together, Atombeat and BioDuro are set to reshuffle the landscape of peptide drug discovery, making it swifter, more efficient, and ultimately more innovative, benefitting both researchers and patients globally.